Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

MOLINA HEALTHCARE, INC. MOH

· Financials · Hospital & Medical Service Plans

FY2025 10-K, filed 2026-02-10
SEC EDGAR

Filing evidence summary

Mixed evidenceCoverage 5/5 core metrics

Operating margin changed -2.5 percentage points from the prior annual period.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Operating margin compressed

    Operating margin changed -2.5 percentage points from the prior annual period.

    Why this surfaced

    Direction threshold: more than +1 percentage point constructive; below -1 point caution. Period end 2025-12-31.

  • Free cash flow was negative

    Latest reported free cash flow was -$636M.

    Why this surfaced

    Free cash flow = operating cash flow minus capital expenditures; positive is supporting evidence, not a valuation conclusion. Period end 2025-12-31.

  • No current rule-based risk flags

    3 filing-based checks were evaluable.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

  • Revenue expanded

    Latest reported annual revenue changed +11.7% from the prior reported annual observation.

    Why this surfaced

    Direction threshold: above +2% constructive; below -2% caution; otherwise monitor. This is not labeled one-year growth when filing periods have a gap. Period end 2025-12-31.

Core trend metrics

Latest annual revenue growth
+11.7%
as of 2025-12-31
Latest annual operating margin
1.7%
as of 2025-12-31
Free cash flow
-$636M
as of 2025-12-31
Debt / equity
0.93x
as of 2025-12-31
ROIC snapshot
7.8%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

0of 3 rule-based checks flagged

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-09-06
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-02-10prior period 2024-12-31 from the same filingView filing
By business segment
Revenue
  • Medicare$1.57B
    100.0%
    no prior

Members sum to $1.57B against $45.4B consolidated (residual $43.9B) - eliminations or corporate lines the filer did not tag on this axis.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,058 US-listed filers · 868 in Financials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$45.4B
97thof 3,301
top third
97thof 540
top third
Revenue growth
latest fiscal-year revenue vs the prior fiscal year
11.8%
65thof 3,137
middle third
64thof 517
middle third
Operating margin
operating income ÷ revenue
1.7%
47thof 2,819
middle third
37thof 233
middle third
Net margin
net income ÷ revenue
1.0%
45thof 3,263
middle third
27thof 533
bottom third
Free-cash-flow margin
(operating cash flow − |capex|) ÷ revenue
-1.4%
32ndof 2,679
bottom third
23rdof 306
bottom third
Return on equity
net income ÷ stockholders' equity (positive equity only)
11.6%
71stof 3,577
top third
68thof 773
top third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
0.1%
98thof 2,895
top third
99thof 421
top third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
28 days
74thof 2,398
top third
63rdof 103
middle third
Cash conversion
operating cash flow ÷ net income (net income > 0)
-1.1×
2ndof 1,954
bottom third
3rdof 574
bottom third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
6.5%
4thof 2,770
bottom third
4thof 649
bottom third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
26.2%
23rdof 2,345
bottom third
26thof 604
bottom third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-1.13×
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
6.5%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
26.2%
change in net operating assets ÷ average net operating assets
Cash-backed years
2 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
1.03×
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 1 changed period
Line itemPeriodFirst reportedLatest filingChangeFilings
Operating cash flow
NetCashProvidedByUsedInOperatingActivities
quarter 2020-03-31$136M
10-Q 2020-05-01
$143M
10-Q 2021-04-29
+5.2%first · latest

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

debt, leases, revenue, segments, contingencies, taxes and more · the filer's own words
Latest quarterly report10-Q FY2026 Q2 · filed 20260723View filing
Commitments and contingencies · 3,123 characters as filed

Commitments and Contingencies Legal Proceedings The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments, as well as various contractual provisions, governing our operations. Compliance with these laws, regulations, and contractual provisions can be subject to government audit, review, and interpretation, as well as regulatory actions. Penalties associated with violations of these laws, regulations, and contractual provisions can include significant fines and penalties, temporary or permanent exclusion from participating in publicly funded programs, a limitation on our ability to market or sell products, the repayment of previously billed and collected revenues, and reputational damage. We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes, and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates, or range of estimates, of reasonably possible and estimable losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments. The outcome of these legal actions are inherently uncertain. An adverse determination in one or more of thes

CommitmentsAndContingenciesDisclosureTextBlock · excerpt; the full note is in the filing

Fair value · 2,340 characters as filed

Fair Value Measurements We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions used to: a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2025 Annual Report on Form 10-K, Note 5, Fair Value Measurements. Our financial instruments measured at fair value on a recurring basis at June 30, 2026, were as follows: Observable Inputs Directly or Indirectly Observable Inputs Unobservable Inputs Total (Level 1) (Level 2) (Level 3) (In millions) Corporate debt securities $ 2,408 $ $ 2,408 $ Mortgage-backed securities 975 975 Asset-backed securities 354 354 Municipal securities 150 150 Other 43 43 Total assets $ 3,930 $ $ 3,930 $ Our financial instruments measured at fair value on a recurring basis at December 31, 2025, were as follows: Observable Inputs Directly or Indirectly Observable Inputs Unobservable Inputs Total (Level 1) (Level 2) (Level 3) (In millions) Corporate debt securities $ 2,465 $ $ 2,465 $ Mortgage-backed securities 953 953 Asset-backed securities 364 364 Municipal se

FairValueDisclosuresTextBlock · excerpt; the full note is in the filing

Long-term debt · 3,163 characters as filed

Debt The following table summarizes our outstanding debt obligations: June 30, 2026 December 31, 2025 (In millions) Non-current long-term debt: 4.375% Notes due June 15, 2028 $ 800 $ 800 3.875% Notes due November 15, 2030 650 650 6.500% Notes due February 15, 2031 850 850 3.875% Notes due May 15, 2032 750 750 6.250% Notes due January 15, 2033 750 750 Deferred debt issuance costs (31) (34) Total $ 3,769 $ 3,766 Senior Notes Each of these notes are senior unsecured obligations of the Parent corporation, Molina Healthcare, Inc., and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina Healthcare, Inc. The senior note indentures contain customary non-financial covenants and change of control provisions. As of June 30, 2026, we were in compliance with all non-financial covenants in the indentures governing the senior notes. The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As discussed below, no amounts were outstanding under the Credit Agreement as of June 30, 2026, so there is no risk of a cross-default under the senior notes. Credit Agreement We are party to a Credit Agreement (the Credit Agreement) which includes a revolving credit facility (Credit Facility) of $1.25 billion, a $15 million swingline sub-facility, a $100

LongTermDebtTextBlock · excerpt; the full note is in the filing

New accounting pronouncements · 418 characters as filed

Recent Accounting Pronouncements Recent accounting pronouncements issued by the Financial Accounting Standards Board (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (SEC) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.

NewAccountingPronouncementsPolicyPolicyTextBlock · excerpt; the full note is in the filing

Segment reporting · 4,400 characters as filed

Segments We currently have four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes long-term services and supports consultative services in Wisconsin and the commercial portion of the business acquired in connection with the ConnectiCare transaction that closed effective February 1, 2025. The key metrics used to assess the performance of our segments are revenue, margin and medical care ratio (MCR). MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the segments after medical or service costs are deducted from revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer, who is our chief operating decision maker, to review results, assess performance, and allocate resources. Such oversight and decision making includes, among others, pricing, approving capital expenditures, and identifying growth opportunities. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resource

SegmentReportingDisclosureTextBlock · excerpt; the full note is in the filing

Significant accounting policies · 11,095 characters as filed

Significant Accounting Policies Cash and Cash Equivalents Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash and cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in Restricted investments in the accompanying consolidated balance sheets. June 30, 2026 2025 (In millions) Cash and cash equivalents $ 4,985 $ 4,499 Restricted cash and cash equivalents 108 93 Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows $ 5,093 $ 4,592 Receivables Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments, as well as pharmacy rebates and other receivables. Government receivables amounted to $2,442 million and $2,365 million at June 30, 2026 and December 31, 2025, respectively. We apply the current expected credit loss model to measure expected credit losses on our receivables based on available information about past events and reasonable and supportable forecasts. Because substan

SignificantAccountingPoliciesTextBlock · excerpt; the full note is in the filing

Source: SEC DERA Financial Statement and Notes data sets (txt.tsv), excerpts of the filer's own note text; the full note is in the linked filing. Excerpts are the first part of each note exactly as tagged in the filing; open the filing for the full text and the tables. Descriptive and educational, not advice.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.